Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07101549 | Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) | not yet recruiting | Phase 1 | 25 | changjianhuaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT02304809 | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé) | active not recruiting | Phase 2 | 216 | UNICANCEROTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06463340 | Study of SGR-3515 In Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 52 | Schrödinger, Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT07098052 | A Study of HDM2020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06484556 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Tao ZhangOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06543056 | A Study of ES014 in Subjects With Advanced Solid Tumors | recruiting | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092748 | A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06220838 | Study SC-101 in Subjects With Advanced Malignancies | recruiting | Phase 1 | 100 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06710158 | Study of SC-102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 120 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07058207 | Weight Management in Obese Cancer Patients During Curative Active Treatment(CANOBESE) | recruiting | N/A | 50 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06428500 | QTX3046 in Patients With KRAS G12D Mutations | active not recruiting | Phase 1 | 240 | Quanta TherapeuticsINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05217693 | A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 288 | Bliss Biopharmaceutical (Hangzhou) Co., LtdINDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05978102 | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 183 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05701709 | Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 395 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06929663 | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 48 | AkesoINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05881525 | NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 18 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06610227 | A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors | active not recruiting | Early Phase 1 | 18 | NING LIOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07046702 | 68Ga-MY6349 PET/CT in Solid Tumors | recruiting | — | 300 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06993870 | Phase I Study of HBT-708 for Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07061639 | A Study of QLS5133 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07057349 | CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer | not yet recruiting | Phase 1 | 40 | Cytosite Biopharma Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06277219 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)(LIGHTSPEED-1) | recruiting | Phase 1 / Phase 2 | 150 | Latticon Antibody Therapeutics, IncINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | enrolling by invitation | Phase 1 | 54 | PharmaEssentiaINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07051161 | Impact of Interventional Endoscopy on Quality of Life in Patients With Acute Respiratory Distress Due to Tumor Compression or Obstruction of the Lower Respiratory Tract(ENDoRA) | not yet recruiting | — | 60 | University Hospital, GrenobleOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT07049458 | Study of CHO-A04 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 62 | Cho Pharma Inc.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07050459 | A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 220 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT06410131 | Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 | recruiting | Phase 1 | 68 | Sound Biopharmaceuticals Ltd.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06415487 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | recruiting | Phase 1 | 30 | Acepodia Biotech, Inc.INDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT07045454 | A Study of MHB118C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06163391 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | recruiting | Phase 1 | 40 | SOTIO Biotech AGINDUSTRY | 5 | Jun 29, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07030478 | A Study to Evaluate the Safety and Tolerability of EP0089 | not yet recruiting | Phase 1 / Phase 2 | 190 | Ellipses PharmaINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07016997 | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2025source: clinicaltrials